QC
LCTX icon

Quantessence Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Quantessence Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,281
Closed -$25.7K – 102
2026
Q1 		$25.7K Buy
+16,281
New +$27.5K 0.13% 62

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Quantessence Capital's LCTX Position: Q2 2026 in Review

Quantessence Capital sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 16,281 shares — an estimated $25.7K sold.

Quantessence Capital first reported a position in LCTX in Q1 2026 and held it in 1 quarter. The position peaked at $25.7K in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Quantessence Capital reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quantessence Capital sold 16,281 Lineage Cell Therapeutics shares in Q2 2026, an estimated $25.7K.
  • Quantessence Capital first reported a position in Lineage Cell Therapeutics in Q1 2026 and held it in 1 quarter.
  • Quantessence Capital's Lineage Cell Therapeutics position peaked at $25.7K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Quantessence Capital's 13F filing for Q2 2026, filed 14 Aug 2026.